Literature DB >> 2435427

Interferons in the treatment of human papillomavirus diseases.

P K Weck, J L Brandsma, J K Whisnant.   

Abstract

A variety of epithelioproliferative benign neoplasms, both trivial and life-threatening, are caused by subtypes of human papillomaviruses. Interferons objectively regress HPV-induced warty disease and affect the regrowth of the transformed epithelium. Interferons effectively control the most serious and potentially life-threatening papillomavirus associated diseases, respiratory papillomatosis and genital warts, but not without the anticipated side effects associated with this potent biological weapon. It is entirely possible and even likely that individual species of interferons act preferentially on certain cells, tissues or organs in response to particular viruses. Combined therapies, such as surgery in combination with interferon, or podophyllin in conjunction with interferon alfa-n1, may prove most efficacious.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2435427     DOI: 10.1007/bf00046428

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  66 in total

1.  Virus interference. I. The interferon.

Authors:  A ISAACS; J LINDENMANN
Journal:  Proc R Soc Lond B Biol Sci       Date:  1957-09-12

2.  Interferon-induced enzymatic activities and their role in the antriviral state.

Authors:  C Baglioni
Journal:  Cell       Date:  1979-06       Impact factor: 41.582

3.  Attempts to detect virus-secific DNA in human tumors. I. Nucleic acid hybridizations with complementary RNA of human wart virus.

Authors:  H zur Hausen; W Meinhof; W Scheiber; G W Bornkamm
Journal:  Int J Cancer       Date:  1974-05-15       Impact factor: 7.396

4.  Laryngeal papilloma: etiologic and therapeutic considerations.

Authors:  T A Cook; J P Brunschwig; J S Butel; A M Cohn; H Goepfert; W E Rawls
Journal:  Ann Otol Rhinol Laryngol       Date:  1973 Sep-Oct       Impact factor: 1.547

5.  Laryngeal papillomatosis.

Authors:  T B Duff
Journal:  J Laryngol Otol       Date:  1971-09       Impact factor: 1.469

6.  Treatment of Juvenile laryngeal papillomatosis with two types of interferon.

Authors:  T J Schouten; W Weimar; J H Bos; C E Bos; C W Cremers; H Schellekens
Journal:  Laryngoscope       Date:  1982-06       Impact factor: 3.325

7.  Interferon and laryngeal papillomatosis. The Iowa experience.

Authors:  B F McCabe; K F Clark
Journal:  Ann Otol Rhinol Laryngol       Date:  1983 Jan-Feb       Impact factor: 1.547

8.  Human leukocyte interferon in therapy of patients with urinary bladder papillomatosis, breast cancer, and melanoma.

Authors:  Z Maricić; P Nola; D Ikić; K Smudj; V Oresić; M Knezević; B Rode; D Jusić; E Soos
Journal:  J Cancer Res Clin Oncol       Date:  1981       Impact factor: 4.553

9.  Human leukocyte interferon produced by E. coli is biologically active.

Authors:  D V Goeddel; E Yelverton; A Ullrich; H L Heyneker; G Miozzari; W Holmes; P H Seeburg; T Dull; L May; N Stebbing; R Crea; S Maeda; R McCandliss; A Sloma; J M Tabor; M Gross; P C Familletti; S Pestka
Journal:  Nature       Date:  1980-10-02       Impact factor: 49.962

10.  Interferon induces morphologic reversion with elimination of extrachromosomal viral genomes in bovine papillomavirus-transformed mouse cells.

Authors:  L P Turek; J C Byrne; D R Lowy; I Dvoretzky; R M Friedman; P M Howley
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

View more
  1 in total

1.  Management of genital warts in women with human leukocyte interferon-alpha vs. podophyllotoxin in cream: a placebo-controlled, double-blind, comparative study.

Authors:  T A Syed; M Khayyami; D Kriz; K Svanberg; R C Kahlon; S A Ahmad; S A Ahmad
Journal:  J Mol Med (Berl)       Date:  1995-05       Impact factor: 4.599

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.